SNP-Based Genetic Risk Stratification for ICD and CRT-D Patient Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying patients at risk for sudden cardiac death (SCD), sudden cardiac arrest (SCA), and heart failure (HF) are inadequate, relying largely on imperfect clinical markers that fail to detect asymptomatic individuals and do not account for genetic predispositions, leading to underutilization of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).
Innovation Solution
Development of genetic markers and diagnostic kits that utilize Single Nucleotide Polymorphisms (SNPs) associated with ventricular arrhythmias, SCD, and HF, combined with computer systems and algorithms to assess patient risk and predict susceptibility to these conditions, allowing for more accurate selection of patients for ICD and CRT-D treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical markers (left ventricular ejection fraction) are used for risk stratification, then the screening process is simple and widely applicable, but the identification accuracy of patients at risk for sudden cardiac death is insufficient and excludes many asymptomatic individuals
Solution Approach 1:
The patent transitions from using a single clinical parameter (left ventricular ejection fraction) to analyzing multiple genetic parameters (SNPs in ion channel genes) to improve risk stratification accuracy. This parameter change enables identification of asymptomatic individuals and those not captured by traditional markers, directly addressing the insufficient identification accuracy while maintaining clinical applicability through genetic testing.
2Reliability
If implantable cardioverter-defibrillators are implanted in all patients who might benefit, then more patients receive potentially life-saving treatment, but the number of unnecessary device implants increases due to inability to accurately identify true high-risk patients
Solution Approach 1:
The patent implements preliminary genetic risk assessment using SNP analysis of ion channel genes before ICD implantation decisions are made. This preliminary action identifies true high-risk patients by detecting genetic predispositions to ventricular arrhythmias, allowing clinicians to confidently implant devices in those who will benefit while avoiding unnecessary implants in low-risk individuals, thus improving treatment efficacy and reducing harmful over-treatment.
3Measurement precision
If comprehensive genetic testing for multiple SNPs is performed, then the genetic basis for risk stratification is enhanced and patient selection accuracy is improved, but the cost and complexity of the diagnostic process increases
Solution Approach 1:
The patent segments the genetic testing process into focused analysis of specific ion channel genes and their associated SNPs rather than performing comprehensive whole-genome sequencing. This segmentation targets the most clinically relevant genetic markers for ventricular arrhythmia risk, improving patient selection accuracy while controlling diagnostic complexity and cost by concentrating resources on high-yield genetic regions.
Data Source
AI summary
Compositions, polynucleotides, probes, kits, methods, computer systems, treatment methods and genetic markers useful for assessing the risk of Sudden Cardiac Death (SCD), Sudden Cardiac Arrest (SCA), Ventricular Arrhythmia (VA), or Heart Failure (HF) are provided herein. The compositions, polynucleotides, probes, kits, methods, computer systems, treatment methods and genetic markers of the invention can provide patients selection for those that can be treated with an ICD or CRT-D based on assessing the presence of one or more Single Nucleotide Polymorphisms (SNPs) associated with any one of Sudden Cardiac Death (SCD), Sudden Cardiac Arrest (SCA), Ventricular Arrhythmia (VA), or Heart Failure (HF), and can indicate treatment with certain drugs such as beta-blockers.